Mouse Monoclonal CUL9 Antibody

The CUL9 antibody is a research tool designed to target the CUL9 (Cullin 9) protein, a member of the cullin family of scaffold proteins that play critical roles in the assembly of E3 ubiquitin ligase complexes. These complexes mediate substrate-specific ubiquitination, marking proteins for proteasomal degradation. CUL9. also known as PARC (p53-associated Parkin-like cytoplasmic protein), is unique among cullins due to its cytoplasmic localization and its interaction with tumor suppressors like p53 and RB1. It is implicated in regulating cellular processes such as apoptosis, DNA damage response, and cell cycle control. Studies suggest CUL9 acts as a tumor suppressor by promoting the degradation of oncoproteins or stabilizing key tumor-suppressive pathways. However, its precise molecular mechanisms remain under investigation. The CUL9 antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunoprecipitation to study protein expression, localization, and interactions in various cancer models and cellular contexts. Its development has advanced understanding of CUL9's role in diseases, particularly in tumorigenesis and neurodegenerative conditions linked to ubiquitin-proteasome dysfunction. Researchers rely on validated CUL9 antibodies to explore its therapeutic potential and biomarker utility.